NCT05121831 - A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

November 6, 2022

Study Completion Date

November 6, 2022

Conditions

Depressive Disorder

Interventions

DRUG

DGX-001Dose 1

Dose level 1 of DGX-001

DRUG

DGX-001 Dose 2

Dose level 2 of DGX-001

DRUG

DGX-001 Dose 3

Dose level 3 of DGX-001

DRUG

DGX-001 Dose 4

Dose level 4 of DGX-001

DRUG

MAD dose panel of DGX-001

Dose levels confirmed through SAD and MAD

Trial Locations (1)

CMAX Clinical Research Address, Adelaide